After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endocrine pancreas and leading to a previously unmet risk-to-benefit balance. Vildagliptin, one of the earliest DPP-4 inhibitors, has been tested across the entire spectrum of type 2 diabetes and has been in clinical use for 20 years. This publication critically reviews the main steps in the clinical development of this agent.
Type 2 diabetes, DPP-4 inhibitors, vildagliptin
Stefano Del Prato has received research support from AstraZeneca,
MSD, Novartis and Boehringer Ingelheim, and consultancy fees from AstraZeneca,
Boehringer Ingelheim, Eli Lilly, GSK, MSD, Novartis, Novo Nordisk, Sanofi, Servier
and Takeda. This article is a short opinion piece and has not been submitted to
external peer reviewers but was reviewed by a member of the Editorial Board
Stefano Del Prato, Department of Clinical and
Experimental Medicine University of Pisa, Via Roma 67,. I-56100 Pisa, Italy.
The publication of this article was supported by Novartis Pharma AG.
This article is published under the Creative Commons Attribution
Noncommercial License, which permits any non-commercial use, distribution,
adaptation and reproduction provided the original author(s) and source are given
Share this Article
Related Content In Diabetes
Controversies in Gestational Diabetes
touchREVIEWS in Endocrinology. 2021;17(2):Online ahead of journal publication.
Gestational diabetes mellitus (GDM), defined as hyperglycaemia identified after the first trimester of pregnancy that is not clearly overt diabetes, impacts approximately 7% of births in the USA; a percentage that has increased in parallel with the prevalence of both obesity and type 2 diabetes over the past 20 years.1–4 The impacts of GDM include hypertensive […]
The DFUC 2020 Dataset: Analysis Towards Diabetic Foot Ulcer Detection
touchREVIEWS in Endocrinology. 2021;17(1):5–11 DOI: https://doi.org/10.17925/EE.2021.17.1.5
Wounds on the feet, known as diabetic foot ulcers (DFUs), are a major complication of diabetes. DFUs can become infected, leading to amputation of the foot or lower limb. Patients who undergo amputation experience significantly reduced survival rates.1 In previous studies, researchers have achieved high accuracy in the recognition of DFUs using machine learning algorithms.2–5 […]
Diabetes Mellitus of Pituitary Origin: A Case Report
touchREVIEWS in Endocrinology. 2021;17(1):68–70 DOI: https://doi.org/10.17925/EE.2021.17.1.68
Acromegaly is a chronic, progressive disease characterized by an excess secretion of growth hormone, and consequently, increased circulating insulin-like growth factor 1 (IGF-1) levels. These patients typically exhibit acral and soft tissue overgrowth, headache, arthritis and visual disturbances. Impaired glucose tolerance and diabetes mellitus are also frequently associated with acromegaly.1 We describe a patient who […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!